Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.2340/actadv.v104.40009Keywords:
COVID-19 Vaccines, Immune System Diseases, Immunosuppression Therapy, Meta-Analysis, Skin DiseasesAbstract
Immunocompromised individuals, primarily attributable to using immunosuppressants, face heightened COVID-19 risks. Despite the proven efficacy of COVID-19 vaccines, their impact on patients with immune-mediated dermatological diseases remains unclear. This study aims to thoroughly examine vaccine immunogenicity, effectiveness, and safety in immune-mediated dermatological disease patients. Clinical studies in adults that compared vaccinated immune-mediated dermatological disease patients with vaccinated healthy controls or unvaccinated immune-mediated dermatological disease patients in terms of vaccine immunogenicity, COVID-19 infection, adverse events, or exacerbation of immune-mediated dermatological diseases were searched via electronic databases. Seventeen studies (1,348,690 participants) were included. Seroconversion rates between immune-mediated dermatological disease patients and healthy controls were not different. However, among individuals aged ≤55 years, immune-mediated dermatological disease patients had lower mean anti-SARS-CoV-2 IgG levels. Immunosuppressed immune-mediated dermatological disease patients also had lower titres and were less likely to achieve T-cell response. In terms of safety, the risk of adverse events was higher in atopic dermatitis patients, but those with psoriasis had a reduced risk. Additionally, immunosuppressed patients had fewer adverse events. Vaccinated immune-mediated dermatological disease patients had a lower risk of COVID-19 infection than unvaccinated patients but a higher risk than healthy controls; however, disease exacerbation may be induced. In conclusion, immune-mediated dermatological diseases showed a reduced vaccine response in our meta-analysis, yet vaccination remained effective against COVID-19 infection and well tolerated.
Downloads
References
Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines 2021; 9: 467.
https://doi.org/10.3390/vaccines9050467 DOI: https://doi.org/10.3390/vaccines9050467
Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol 2021; 12: 714170.
https://doi.org/10.3389/fimmu.2021.714170 DOI: https://doi.org/10.3389/fimmu.2021.714170
Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty 2021; 10: 132.
https://doi.org/10.1186/s40249-021-00915-3 DOI: https://doi.org/10.1186/s40249-021-00915-3
Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med 2022; 20: 200.
https://doi.org/10.1186/s12916-022-02397-y DOI: https://doi.org/10.1186/s12916-022-02397-y
Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021; 11: 22777.
https://doi.org/10.1038/s41598-021-02321-z DOI: https://doi.org/10.1038/s41598-021-02321-z
Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021; 19: 173.
https://doi.org/10.1186/s12916-021-02059-5 DOI: https://doi.org/10.1186/s12916-021-02059-5
Manuel O, Estabrook M. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33: e13511.
https://doi.org/10.1111/ctr.13511 DOI: https://doi.org/10.1111/ctr.13511
Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997; 102: 2-9.
https://doi.org/10.1016/S0002-9343(97)00003-X DOI: https://doi.org/10.1016/S0002-9343(97)00003-X
Coronavirus Disease 2019 (COVID-19) Treatment guidelines. Bethesda (MD): National Institutes of Health (US); 2021.
Jayasinghe S, Patel C, Armstrong L, Chiu C, Macartney K, Flanagan K, et al. ATAGI Targeted Review 2021: the national COVID-19 vaccination program. Commun Dis Intell (2018) 2023; 47.
https://doi.org/10.33321/cdi.2023.47.20 DOI: https://doi.org/10.33321/cdi.2023.47.20
Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine 2023; 59: 101965.
https://doi.org/10.1016/j.eclinm.2023.101965 DOI: https://doi.org/10.1016/j.eclinm.2023.101965
Sakuraba A, Luna A, Micic D. Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology 2022; 162: 88-108.
https://doi.org/10.1053/j.gastro.2021.09.055 DOI: https://doi.org/10.1053/j.gastro.2021.09.055
Lee ARYB, Wong SY, Tay SH. Booster COVID-19 vaccines for immune-mediated inflammatory disease patients: a systematic review and meta-analysis of efficacy and safety. Vaccines 2022; 10: 668.
https://doi.org/10.3390/vaccines10050668 DOI: https://doi.org/10.3390/vaccines10050668
Sakuraba A, Luna A, Micic D. A systematic review and meta-analysis of serologic response following coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients. Viruses 2022; 14: 1822.
https://doi.org/10.3390/v14081822 DOI: https://doi.org/10.3390/v14081822
Sood A, Tran M, Murthy V, Gonzalez E. Immunogenicity and safety of SARS-CoV-2 vaccination in patients with rheumatic diseases: a systematic review and meta-analysis. J Clin Rheumatol 2022; 28: 381-389.
https://doi.org/10.1097/RHU.0000000000001871 DOI: https://doi.org/10.1097/RHU.0000000000001871
Sung KY, Chang TE, Wang YP, Lin CC, Chang CY, Hou MC, et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systemic review and meta-analysis. J Chin Med Assoc 2022; 85: 421-430.
https://doi.org/10.1097/JCMA.0000000000000682 DOI: https://doi.org/10.1097/JCMA.0000000000000682
Bhurwal A, Mutneja H, Bansal V, Goel A, Arora S, Attar B, et al. Effectiveness and safety of SARS-CoV-2 vaccine in inflammatory bowel disease patients: a systematic review, meta-analysis and meta-regression. Aliment Pharmacol Ther 2022; 55: 1244-1264.
https://doi.org/10.1111/apt.16913 DOI: https://doi.org/10.1111/apt.16913
James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, et al. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis 2022; 54: 713-721.
https://doi.org/10.1016/j.dld.2022.03.005 DOI: https://doi.org/10.1016/j.dld.2022.03.005
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: 71.
https://doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605.
https://doi.org/10.1007/s10654-010-9491-z DOI: https://doi.org/10.1007/s10654-010-9491-z
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.
https://doi.org/10.1136/bmj.i4919 DOI: https://doi.org/10.1136/bmj.i4919
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
https://doi.org/10.1186/1471-2288-14-135 DOI: https://doi.org/10.1186/1471-2288-14-135
Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet 2021; 397: 1347-1348.
https://doi.org/10.1016/S0140-6736(21)00527-4 DOI: https://doi.org/10.1016/S0140-6736(21)00527-4
Graceffa D, Sperati F, Bonifati C, Spoletini G, Lora V, Pimpinelli F, et al. Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics. Front Med 2022; 9: 961904.
https://doi.org/10.3389/fmed.2022.961904 DOI: https://doi.org/10.3389/fmed.2022.961904
Kridin K, Schonmann Y, Onn E, Bitan DT, Weinstein O, Cohen AD. Determinants and effectiveness of BNT162b2 mRNA vaccination among patients with atopic dermatitis: a population-based study. Am J Clin Dermatol 2022; 23: 385-392.
https://doi.org/10.1007/s40257-022-00672-5 DOI: https://doi.org/10.1007/s40257-022-00672-5
Özgen Z, Aksoy H, Akın Çakıcı Ö, Koku Aksu AE, Erdem O, Kara Polat A, et al. COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients. Dermatol Ther 2022; 35: e15417.
https://doi.org/10.1111/dth.15417 DOI: https://doi.org/10.1111/dth.15417
Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol 2022; 4: 42-52.
https://doi.org/10.1016/S2665-9913(21)00333-7 DOI: https://doi.org/10.1016/S2665-9913(21)00333-7
Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol 2021; 3: 627-637.
https://doi.org/10.1016/S2665-9913(21)00212-5 DOI: https://doi.org/10.1016/S2665-9913(21)00212-5
Pakhchanian H, Raiker R, Wolf M, Trotter SC. Examining the risk of breakthrough infection and COVID-19 vaccination safety in patients with atopic dermatitis. Br J Dermatol 2022; 187: 251-253.
https://doi.org/10.1111/bjd.21038 DOI: https://doi.org/10.1111/bjd.21038
Huang YW, Tsai TF. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med 2021; 8: 812010.
https://doi.org/10.3389/fmed.2021.812010 DOI: https://doi.org/10.3389/fmed.2021.812010
Koç Yıldırım S, Demirel Öğüt N, Erbağcı E. Retrospective evaluation of patients with chronic spontaneous urticaria using omalizumab during the COVID-19 pandemic. J Cosmet Dermatol 2022; 21: 431-434.
https://doi.org/10.1111/jocd.14725 DOI: https://doi.org/10.1111/jocd.14725
Chanprapaph K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, et al. A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatologic diseases. Br J Dermatol 2023; 188: 268-277.
https://doi.org/10.1093/bjd/ljac045 DOI: https://doi.org/10.1093/bjd/ljac045
Cristaudo A, Graceffa D, Pimpinelli F, Sperati F, Spoletini G, Bonifati C, et al. Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. J Eur Acad Dermatol Venereol 2022; 36: 266-268.
https://doi.org/10.1111/jdv.17861 DOI: https://doi.org/10.1111/jdv.17861
Piros ÉA, Cseprekál O, Görög A, Hidvégi B, Medvecz M, Szabó Z, et al. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals: prospective observational cohort study. Dermatol Ther 2022; 35: e15408.
https://doi.org/10.1111/dth.15408
Pavlotsky F, Segal Z, Barzilai A. Antibody response to BNT162b2 vaccine in immune modifiers-treated psoriatic patients. J Psoriasis Psoriatic Arthritis 2022; 7: 24-28.
https://doi.org/10.1177/24755303211056059 DOI: https://doi.org/10.1177/24755303211056059
Seree-Aphinan C, Chanprapaph K, Rattanakaemakorn P, Setthaudom C, Suangtamai T, Pomsoong C, et al. Inactivated COVID-19 vaccine induces a low humoral immune response in a subset of dermatological patients receiving immunosuppressants. Front Med 2021; 8: 769845.
https://doi.org/10.3389/fmed.2021.769845 DOI: https://doi.org/10.3389/fmed.2021.769845
Megna M, Potestio L, Battista T, Camela E, Genco L, Noto M, et al. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin Exp Dermatol 2022; 47: 2310-2312.
https://doi.org/10.1111/ced.15395 DOI: https://doi.org/10.1111/ced.15395
Jena A, Mishra S, Deepak P, Kumar MP, Sharma A, Patel YI, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev 2022; 21: 102927.
https://doi.org/10.1016/j.autrev.2021.102927 DOI: https://doi.org/10.1016/j.autrev.2021.102927
Jena A, James D, Singh AK, Dutta U, Sebastian S, Sharma V. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022; 20: 1456-1479.
https://doi.org/10.1016/j.cgh.2022.02.030 DOI: https://doi.org/10.1016/j.cgh.2022.02.030
Sakuraba A, Luna A, Micic D. Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis. J Hematol Oncol 2022; 15: 15.
https://doi.org/10.1186/s13045-022-01233-3 DOI: https://doi.org/10.1186/s13045-022-01233-3
Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, et al. Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatol Int 2021; 41: 1429-1440.
https://doi.org/10.1007/s00296-021-04910-7 DOI: https://doi.org/10.1007/s00296-021-04910-7
Kostianovsky A, Charles P, Alves JF, Goulet M, Pagnoux C, Le Guern V, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012; 30: S83-S89.
Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 623-625.
https://doi.org/10.1136/ard.61.7.623 DOI: https://doi.org/10.1136/ard.61.7.623
Erkek E, Ayaslioglu E, Erkek AB, Kurtipek GS, Bagci Y. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol 2005; 20: 1508-1511.
https://doi.org/10.1111/j.1440-1746.2005.03903.x DOI: https://doi.org/10.1111/j.1440-1746.2005.03903.x
McMahan ZH, Bingham CO 3rd. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther 2014; 16: 506.
https://doi.org/10.1186/s13075-014-0506-0 DOI: https://doi.org/10.1186/s13075-014-0506-0
Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62: 64-74.
https://doi.org/10.1002/art.25034 DOI: https://doi.org/10.1002/art.25034
Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing 2019; 16: 25.
https://doi.org/10.1186/s12979-019-0164-9 DOI: https://doi.org/10.1186/s12979-019-0164-9
Stiasny K, Aberle JH, Keller M, Grubeck-Loebenstein B, Heinz FX. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One 2012; 7: e34145.
https://doi.org/10.1371/journal.pone.0034145 DOI: https://doi.org/10.1371/journal.pone.0034145
Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis 2021; 73: 2065-2072.
https://doi.org/10.1093/cid/ciab381 DOI: https://doi.org/10.1093/cid/ciab381
Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T cell responses elicited by COVID-19 vaccines or infection are expected to remain robust against Omicron. Viruses 2022; 14: 79.
https://doi.org/10.3390/v14010079 DOI: https://doi.org/10.3390/v14010079
Seree-Aphinan C, Ratanapokasatit Y, Suchonwanit P, Rattanakaemakorn P, O-Charoen P, Pisitkun P, et al. Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients. Front Immunol 2023; 14: 1138765.
https://doi.org/10.3389/fimmu.2023.1138765 DOI: https://doi.org/10.3389/fimmu.2023.1138765
Seree-Aphinan C, Suchonwanit P, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, et al. Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: a prospective cohort study. J Eur Acad Dermatol Venereol 2023; 37: e572-e575.
https://doi.org/10.1111/jdv.18890 DOI: https://doi.org/10.1111/jdv.18890
Avallone G, Cavallo F, Astrua C, Caldarola G, Conforti C, De Simone C, et al. Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience. J Eur Acad Dermatol Venereol 2022; 36: e876-e879.
https://doi.org/10.1111/jdv.18386 DOI: https://doi.org/10.1111/jdv.18386
Nakashima C, Kato M, Otsuka A. Cutaneous manifestations of COVID-19 and COVID-19 vaccination. J Dermatol 2023; 50: 280-289.
https://doi.org/10.1111/1346-8138.16651 DOI: https://doi.org/10.1111/1346-8138.16651
Maronese CA, Zelin E, Avallone G, Moltrasio C, Romagnuolo M, Ribero S, et al. Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic. Front Med 2022; 9: 996288.
https://doi.org/10.3389/fmed.2022.996288 DOI: https://doi.org/10.3389/fmed.2022.996288
von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, et al. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 2014; 32: 5696-5702.
https://doi.org/10.1016/j.vaccine.2014.08.022 DOI: https://doi.org/10.1016/j.vaccine.2014.08.022
Boekel L, Stalman EW, Wieske L, Hooijberg F, van Dam KPJ, Besten YR, et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol 2022; 4: e417-e429.
Stalman EW, Wieske L, van Dam KPJ, Kummer LY, van Kempen ZLE, Killestein J, et al. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2022; 81: 1757-1766.
https://doi.org/10.1136/ard-2022-222904 DOI: https://doi.org/10.1136/ard-2022-222904
Cao C, Qiu F, Lou C, Fang L, Liu F, Zhong J, et al. Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases. Respir Res 2022; 23: 133.
https://doi.org/10.1186/s12931-022-02054-1 DOI: https://doi.org/10.1186/s12931-022-02054-1
Piros ÉA, Cseprekál O, Görög A, Hidvégi B, Medvecz M, Szabó Z, et al. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals: prospective observational cohort study. Dermatol Ther 2022; 35: e15408.
https://doi.org/10.1111/dth.15408 DOI: https://doi.org/10.1111/dth.15408
Baloghová J, Kampe T, Kolarčik P, Hatalová E. Vaccination, risk factors and outcomes of COVID-19 infection in patients with psoriasis: a single centre real-life experience from eastern Slovakia. Viruses 2022; 14: 1646.
https://doi.org/10.3390/v14081646 DOI: https://doi.org/10.3390/v14081646
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Sonphet Chirasuthat, Yanisa Ratanapokasatit, Kunlawat Thadanipon, Kumutnart Chanprapaph
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
